6,678 trials
Well-differentiated Pancreatic Neuroendocrine Tumor
Primary: Progression-Free Survival (PFS): Investigator Assessment — 13.2; 13.0 months
Perioperative Inflammatory Response
Primary: Median Concentration of Aspartate Aminotransferase (AST) — 24.5; 24.5; 21.0; 20.0 U/L
Atopic Dermatitis
Primary: Investigator Global Assessment of Improvement — 2; 2; 2 units on a scale
Atrial Fibrillation
Primary: Number of Participants With Atrial Fibrillation Recurrence From 6 Months up to 12 Months — 4; 6 Participants with AF recurrence
Pulmonary Hypertension · Diastolic Left Ventricular Dysfunction
Primary: Percent Change in mPAP, PAOP and Pulmonary Vascular Resistance (PVR) — -21; -39; -4.0 percentage change
Cardiovascular Diseases · Heart Diseases · Heart Failure
Primary: Urine Output — 6498; 5784 mL — p=0.853
Fracture · Pain, Postoperative
Primary: Opioid Consumption During the 48 Hours After Surgery — 51; 87 mg — p=0.0072
Hand Hygiene Effectiveness
Primary: Bacterial Colony Forming Units Present on Hand Prints After Time Spent in Common Areas — 2.17; 1.81 log(10) transformed CFU
Microvascular Angina
Primary: Coronary Flow Reserve — 1.6; 1.6; 1.9; 1.6 ratio
Bipolar Disorder
Primary: Mean Change in CGI-BP-OS After 1 Week of Treatment — -1.4; .8 units on a scale — p=.08
Postoperative Pain
Primary: Total Narcotic Usage at 48 Hours — 2.44; 2.88 mg
Acute HIV Infection · HIV Infections
Primary: Number of Participants Without Virologic Failure at Week 24 — 81 Participants
Total Knee Replacement
Primary: Number of Days Until a Dry Wound — 3.6 days
Moderate to Severe Secondary Hyperparathyroidism · Stage 5 Chronic Kidney Diseases
Primary: Mean Erythropoietin Dose Per Visit — 35.8; 22.2; 22.7; 4.7 µg
Infection, Human Immunodeficiency Virus
Primary: Plasma Lamivudine Area Under the Plasma Concentration Time Curve (AUC) From Time Zero to the Last Quantifiable Time Point (AUC[0-t]), AUC From Time Zero Extrapolated to…